Cerberus Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Cerberus Ventures/Activity

Cerberus Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

5 investments· MAY 2026 – AUG 2026Show all

Investment

Led Riven Systems' $7.9M pre-seed round for AI-driven critical minerals processing.

Riven Systems

Riven Systems Cerberus Ventures

axios.comAUG 13, 2026

AUG 13, 2026

Investment

Participated in Photon Queue's oversubscribed $4M seed round for room-temperature quantum memory hardware.

Photon Queue

Photon Queue Cerberus Ventures

thequantuminsider.comJUL 21, 2026

JUL 21, 2026

Investment

Participated in AquaPoro's $5M seed round for atmospheric water generation technology.

AquaPoro

AquaPoro Cerberus Ventures

businesswire.comJUN 24, 2026

JUN 24, 2026

Investment

Participated in Layup Parts' $42M Series A led by Marlinspike for its composite-manufacturing marketplace.

Layup Parts

Layup Parts Cerberus Ventures

techcrunch.comJUN 2, 2026

JUN 2, 2026

Investment

Co-led Star Catcher's oversubscribed $65M Series A to build the first space-based power grid.

Star Catcher

Star Catcher Cerberus Ventures

prnewswire.comMAY 12, 2026

MAY 12, 2026

Milestone

Portfolio company PrismML launched the world's first commercially viable 1-bit AI model, built on Caltech research.

Prism ML

Prism ML Cerberus Ventures

prnewswire.comMAR 31, 2026

MAR 31, 2026

Investment

Led Virchow Medical's $4M seed round for biopsy specimen stewardship technology; Chenny Zhang joined the board.

Virchow Medical

Virchow Medical Cerberus Ventures

virchowmed.comMAR 24, 2026

MAR 24, 2026

Milestone

Portfolio company Syntis Bio dosed its first patient in the Phase 1/1b clinical trial of SYNT-101 for obesity.

Syntis Bio

Syntis Bio Cerberus Ventures

syntis.bioMAR 3, 2026

MAR 3, 2026

Investment

Led Ansa Biotechnologies' $54.4M Series B financing for its synthetic DNA synthesis platform.

Ansa Bio

Ansa Bio Cerberus Ventures

cerberus.comOCT 2025

OCT 2025

New Fund

Cerberus Ventures announced a $74.72M first close for its inaugural venture fund, Cerberus Venture One.

Cerberus Venture One (first close)

Cerberus Ventures

pitchbook.comAPR 11, 2025

APR 11, 2025